Form 4: Aprea Therapeutics Director Equity Grant Disclosure

Director Richard Peters received a grant of restricted stock units and stock options as part of annual board compensation.

Summary

• Director Richard Peters was granted 3,135 restricted stock units (RSUs) on June 16, 2026.
• Director Richard Peters was granted 12,555 stock options with an exercise price of $0.7293 on June 16, 2026.
• Both the RSUs and the stock options are scheduled to vest in full on June 16, 2027, contingent upon continued service on the board.
• Following these transactions, the director holds 6,254 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard retention mechanism for board members via one-year cliff vesting.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though minor in scale.

Risks

• Vesting is subject to continued service, creating potential turnover risk if board composition changes.
• Market price volatility could impact the future value of the granted options.

Future Outlook

The equity grants are subject to continued service through June 16, 2027, at which point they will vest in full.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation common in the biotechnology sector, where equity is frequently used to attract and retain board expertise.

Comparison to Industry Standards

• The use of one-year cliff vesting for director equity is consistent with standard corporate governance practices for small-cap biotech firms.
• The grant size is typical for non-executive director annual compensation packages.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity awards on June 16, 2027.

Key Dates

Keywords

Aprea Therapeutics, APRE, Form 4, Insider Trading, Equity Compensation, Director Compensation